FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study - Cremolini, C; Loupakis, F; Antoniotti, C (Lancet Oncol, 2015)
et al.